文献速递血栓与止血

皮下注射长效重组凝血因子Ⅷ在重型血友病A经治患者中的药代动力学、免疫原性、安全性和初步疗效(alleviate 1)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
PubMed 文献 · J Thromb Haemost · 2019-11-15

alleviate 1研究评估皮下注射turoctocog alfa pegol(s.c. N8-GP)在成人或青少年重型血友病A经治患者中的药代动力学、免疫原性、安全性和初步疗效。A部分24例患者单次给药(12.5、25、50或100 IU/kg),B部分26例患者每日皮下注射(<60 kg者2000 IU,≥60 kg者4000 IU)3个月。每日皮下预防给药耐受性良好且有效,稳态谷浓度FVIII活性接近10%,但5例患者出现抗N8-GP结合抗体,其中1例发生FVIII抑制物,s.c. N8-GP的进一步临床开发已暂停。

要点

  • 皮下注射N8-GP在重型血友病A经治患者中抗体发生率较高。
  • 每日皮下预防给药稳态谷浓度FVIII活性接近10%。
  • 5例出现抗N8-GP结合抗体,其中1例发生FVIII抑制物。

核心结论

  • 皮下注射N8-GP在重型血友病A经治患者中与高抗体发生率相关,进一步临床开发已暂停。

研究设计与样本

  • alleviate 1(NCT02994407)为在成人或青少年重型血友病A经治患者中开展的I期研究。
  • A部分24例患者单次皮下注射N8-GP(12.5、25、50或100 IU/kg),每组6例。
  • B部分26例患者每日皮下注射N8-GP(<60 kg者2000 IU,≥60 kg者4000 IU)3个月。

主要发现

  • 单次皮下注射N8-GP支持剂量线性。
  • 每日皮下预防给药耐受性良好且有效,稳态平均谷浓度FVIII活性接近10%。
  • 5例患者在42至91个暴露日后出现抗N8-GP结合抗体,其中1例发生FVIII抑制物。
  • 5例患者中4例抗N8-GP抗体出现与FVIII血浆活性下降相关。
  • 预防期间5例患者共报告9次需要治疗的出血事件。

临床怎么用

  • 皮下N8-GP因抗体高发生率已暂停开发,暂不用于重型血友病A经治患者的临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing. OBJECTIVES: Evaluate the pharmacokinetics (PK), immunogenicity, safety, and preliminary efficacy of s.c. administration of turoctocog alfa pegol (s.c. N8-GP) in adult or adolescent previously treated patients (PTPs) with severe hemophilia A (alleviate 1; NCT02994407). PATIENTS/METHODS: In part A, 24 PTPs received a single dose of s.c. N8-GP (12.5, 25, 50, or 100 IU/kg) with 6 patients per cohort. PK modelling of data from part A supported a suitable dose for part B. Part B comprised a multiple dose trial in 26 PTPs; patients <60 kg received 2000 IU and patients ≥60 kg received 4000 IU s.c. N8-GP daily for 3 months. RESULTS: Single-dose s.c. N8-GP supported dose linearity. Daily prophylaxis with s.c. N8-GP appeared well tolerated and efficacious, achieving a mean trough FVIII activity close to 10% at steady state. Five patients developed anti-N8-GP binding antibodies after 42 to 91 exposure days, one of whom developed an inhibitor to FVIII. Anti-N8-GP antibody appearance was associated with a decline in FVIII plasma activity in four of the five patients. Five patients reported a total of nine treatment-requiring bleeding episodes during prophylaxis. CONCLUSIONS: Subcutaneous administration of N8-GP is associated with a high incidence of antibodies in PTPs with severe hemophilia A. Further clinical development of s.c. N8-GP has been suspended.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Klamroth R, Feistritzer C, Friedrich U, et al. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1). J Thromb Haemost. 2019. PMID: 31618804. doi:10.1111/jth.14660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。